SEARCH

SEARCH BY CITATION

References

  • 1
    Johnson TN. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology 2003; 192: 3748.
  • 2
    Breant V, Charpiat B, Sab JM, Maire P, Jelliffe RW. How many patients and blood levels are necessary for population pharmacokinetic analysis? Eur J Clin Pharmacol 1996; 51: 2838.
  • 3
    Lee PID. Design and power of a population pharmacokinetic study. Pharm Res 2001; 18: 7582.
  • 4
    Johnson TN, Rostami-Hodjegan A, Goddard JM, Tanner MS, Tucker GT. Contribution of midazolam and its 1-hydroxy metabolite to pre-operative sedation in children: a pharmacokinetic-pharmacodynamic analysis. Br J Anaesth 2002; 89: 42837.
  • 5
    Matthews A, Johnson TN, Rostami-Hodjegan A, Chakrapani A, Wraith JE, Moat SJ, Bonham JR, Tucker GT. An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria. Br J Clin Pharmacol 2002; 54: 1406.
  • 6
    Mandema JW, Tuk B, Van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992; 51: 71528.
  • 7
    Bonate PL. Clinical trial simulation in drug development. Pharm Res 2000; 17: 2526.
  • 8
    CDER. Pediatric Decision Tree, http://www.fda.gov/cder/mapp/4000.4.pdf 27 April 2004.
  • 9
    Marshall JD, Wells TG, Letzig L, Kearns GL. Pharmacokinetics and pharmacodynamics of bumetanide in critically ill pediatric patients. J Clin Pharmacol 1998; 38: 9941002.
  • 10
    Marshall JD, Kearns GL. Developmental pharmacodynamics of cyclosporine. Clin Pharmacol Ther 1999; 66: 6675.
  • 11
    Tran A, Rey E, Pons G, Pariente-Khayat A, D’Athis P, Sallerin V, Dupont C. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther 2002; 71: 35967.
  • 12
    De Wildt SN, Kearns GL, Sie SD, Hop WCJ, Van Den Anker JN. Pharmacodynamics of intravenous and oral midazolam in preterm infants, PhD Thesis, Developmental aspects of midazolam metabolism. University of Rotterdam, 2001.
  • 13
    Stergaard D, Gätke MR, Berg H, Rasmussen SN, Viby-Mogensen J. The pharmacodynamics and pharmacokinetics of mivacurium in children. Acta Anaesthesiol Scand 2002; 46: 5128.
  • 14
    Abdel-Rahman SM, Johnson FK, Connor JD, Staiano A, Dupont C, Tolia V, Winter H, Gauthier-Dubois G, Kearns GL. Developmental pharmacokinetics and pharmacodynamics of nizatidine. J Pediatr Gastroenterol Nutr 2004; 38: 44251.
  • 15
    Orenstein SR, Blumer JL, Faessel HM, McGuire JA, Fung K, Li BUK, Lavine JE, Grunow JE, Treem WR, Ciociola AA. Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro- oesophageal reflux. Aliment Pharmacol Ther 2002; 16: 899907.
  • 16
    Saldien V, Vermeyen KM, Wuyts FL. Target-controlled infusion of rocuronium in infants, children, and adults: a comparison of the pharmacokinetic and pharmacodynamic relationship. Anesth Analg 2003; 97: 449.
  • 17
    Lear S, Elshoff JP, Meibohm B, Weil J, Mir TS. Development of a Pediatric Dosing Regimen for Sotolol. 9th European Society for Developmental Pharmacology meeting, 2004, Marberg, Germany.
  • 18
    Takahashi H, Ishikawa S, Nomoto S, Nishigaki Y, Ando F, Kashima T, Kimura S, Kanamori M, Echizen H. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther 2000; 68: 54155.
  • 19
    Price PS, Conolly RB, Chaisson CF, Gross EA, Young JS, Mathis ET, Tedder DR. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 2003; 33: 469503.
  • 20
    Ellis KJ. Human body composition: in vivo methods. Physiol Rev 2000; 80: 64980.
  • 21
    Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinetics 2002; 41: 95998.
  • 22
    Johnson TN, Rostami-Hodjegan A, Tucker GT. A comparison of methods to predict drug clearance in neonates, infants and children. Br J Clin Pharmacol 2004; 57: 6778.
  • 23
    Price K, Haddad S, Krishnan K. Physiological modelling of age specific changes in PK of organic chemicals in children. J Toxicol Environ Health Part A 2003; 66: 41733.
  • 24
    Gentry PR, Covington TR, Clewell Lll HJ. Evaluation of the potential impact of PK differences on tissue dosimetry in offspring during pregnancy and lactation. Reg Toxicol Pharmacol 2003; 38: 116.
  • 25
    Ginsberg G, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M, Smolenski S, Golbe R. PBPK modelling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents. J Toxicol Environ Health Part A 2004; 67: 297329.
  • 26
    Houston JB, Carlile DJ. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 1997; 29: 891922.
  • 27
    Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283: 4658.
  • 28
    Tooley A, Rostami-Hodjegan A, Lennard MS, Tucker GT. Acute inhibition of methadone metabolism by ritonavir: projection of interaindividual variability from in vitro data. Br J Clin Pharmacol 1999; 48: 883P884P.
  • 29
    Yang JS, Rostami-Hodjegan A, Tucker GT. Prediction of fluconazole interaction with midazolam and triazolam: incorporating population variability. Br J Clin Pharmacol 2001; 52: 484P.
  • 30
    Yang JS, Rostami-Hodjegan A, Tucker GT. Prediction of ritonavir interaction with sildenafil (Viagra): incorporating population variability. Br J Clin Pharmacol 2002; 53: 483P.
  • 31
    Proctor NJ, Smith CY, Rostami-Hodjegan A, Tucker GT. Population clearance prediction of 13 drugs using SIMCYP™. Pharmacologist 2002; 44 (Suppl. 1): LB87.
  • 32
    Johnson TN, Sabzghabaee A, Rostami-Hodjegan A, Tucker GT. Prediction of age related changes in midazolam clearance in children using SIMCYP. Br J Clin Pharmacol 2003; 55: 4323P.
  • 33
    Johnson TN, Tucker GT, Rostami-Hodjegan A. Prediction of Drug Clearance from in vitro Data for 12 Drugs in Neonates, Infants and Children, Proceeding of the 7th International ISSX Meeting 2004; Vancouver, Canada.
  • 34
    Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997; 6: 27591,.
  • 35
    Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, Tucker GT. Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol 2003; 56: 43340,.
  • 36
    International Commission on Radiological Protection. Report of the Task Force on Reference Man. Oxford: Pergamon Press,1975.